Unusual findings of acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): A multicenter study

International Journal of Laboratory Hematology
Xubo GongXiaoying Zhao

Abstract

AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) [inv(3)/t(3;3)] was very rare. Currently, most reports of AML-inv(3)/t(3;3) were from Western countries, and few reports were from Asian countries. Racial differences in patients with AML-inv(3)/t(3;3) are still unknown. Between January 1996 and April 2018, a total of 37 AML cases with inv(3)/t(3;3) were studied retrospectively. They were collected from 2229 primary AML cases performed with conventional cytogenetic analysis (37/2229, 1.66%). Here, some differences were found by comparing our data with those from Western countries. In our series, AML with inv(3)(q21q26) had a lower incidence than that with t(3;3)(q21;q26) (11 vs 26 cases). Our patients seemed to be more younger (median, 43 years) and have lower hemoglobin concentrations (median, 73 g/L) and higher platelet count (median, 351 × 109 /L). A higher incidence of acute monoblastic and monocytic leukemia (45.9%) was observed in our patients. Immunophenotypic studies showed that CD38 (30.8%) was not so frequently expressed as that in the earlier reports. Mutations analysis showed a high frequency of NRAS mutations (45.0%), followed by SF3B1(15.0%), GATA2(15.0%), FLT3-ITD(10.0%), C-Kit/D816(5.0%), and CEBPA(5.0%), withou...Continue Reading

References

Oct 1, 1996·Genome Research·C A HeidP M Williams
Dec 28, 1999·Leukemia & Lymphoma·S FujisawaY Ishigatsubo
Aug 8, 2002·Cancer Genetics and Cytogenetics·Yi-Kong KeungMark Pettenati
May 13, 2004·Genes, Chromosomes & Cancer·Idoya LahortigaMaría D Odero
Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Liang-In LinHwei-Fang Tien
Sep 29, 2009·Leukemia Research·Bruno C MedeirosAsh A Alizadeh
Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sanne LugthartHartmut Döhner
Nov 30, 2010·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Jianlan SunPei Lin
Feb 14, 2015·Hematology·Jose Maria RayaUNKNOWN Grupo Español de Citología Hematológica (GECH), Working Group into the Sociedad Española de Hematología y Hemoterapia (SEHH)
Sep 16, 2016·Archives of Pathology & Laboratory Medicine·Huan-You Wang, Hooman H Rashidi
Mar 25, 2017·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Zhihong HuShimin Hu

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.